Core Viewpoint - Dongyangguang Pharmaceutical is pioneering an innovative capital operation by launching the first "H-share absorption merger privatization + introduction listing" in the Hong Kong market, aiming for overall listing and resource integration [1][2] Group 1: Capital Market Operations - Dongyangguang Pharmaceutical completed the last trading day of Dongyangguang Changjiang Pharmaceutical on July 29, officially starting its innovative capital operation [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on the Hong Kong Stock Exchange on August 7, creating a new paradigm for asset securitization in Chinese innovative pharmaceutical companies [1] - The absorption merger allows the listing entity to issue H-shares to minority shareholders of Dongyangguang Changjiang Pharmaceutical, facilitating a seamless transition to overall listing [1] Group 2: Strategic Implications - This move breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The operation serves as a model for industrial integration and international development, aligning with national strategies to optimize capital market structures [1] Group 3: Company Profile - Dongyangguang Pharmaceutical focuses on drug research, production, and commercialization, specializing in innovative drugs, including improved new drugs, generic drugs, and biosimilars [2] - The company adheres to principles of innovation, internationalization, and sustainability, driven by independent research and development, and targets treatment areas such as infections, chronic diseases, and tumors [2] - Dongyangguang Pharmaceutical has established a mature and well-circulated business model, progressing towards the goal of becoming a world-class innovative pharmaceutical company [2]

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and is set to launch on the Hong Kong Stock Exchange, marking the first instance of "H-share absorption merger privatization + introduction listing" in the market [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on August 7, 2023, creating a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - This listing does not involve new share issuance or fundraising; instead, it involves the absorption merger of its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, allowing small shareholders to exchange their shares for H-shares [1] Group 2 - Industry insiders note that this approach breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The move is seen as a model for resource integration and capital upgrade, providing a reference for industrial consolidation and international development, aligning with national strategies to optimize capital market structures [1] - After the Hong Kong listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [1][2]